Mobotinib (mobosetinib) side effects and hazards

Mobosetinib is a targeted therapy for non-small cell lung cancer with insertion mutations in EGFRexon20. Although it has brought new treatment options to many patients, some side effects and potential hazards may also occur during its use.

1.Gastrointestinal reactions: including nausea, vomiting, loss of appetite and diarrhea. These reactions may be related to the irritation of the gastrointestinal tract by the drug. They are usually more obvious at the beginning of treatment, but may gradually lessen as treatment continues.

2.Skin problems: such as rash, dry skin, itching and paronychia, etc. These skin reactions may be caused by irritation of the skin tissue or an allergic reaction to the drug.

3.Fatigue and weakness: Patients may feel persistent fatigue and weakness while taking mobotinib, which may be related to the consumption of the body during the metabolism and excretion of the drug.

4. Elevated liver enzymes: Some patients will experience increased liver enzymes (such as alanine aminotransferase, aspartate aminotransferase) after taking mobotinib, which may indicate that the drug has a certain impact on the liver.

5.Arrhythmia risk: Mobotinib may cause heart rate-corrected QT (QTc) interval prolongation, increase the risk of arrhythmia, and may even be life-threatening. Therefore, ECG and electrolyte levels should be monitored before starting treatment and periodically during treatment.

6.Lung damage: This product may also cause lung damage such as interstitial lung disease/ lung inflammation, which is also a potentially serious side effect. If pulmonary symptoms such as dyspnea, cough, and fever occur, treatment should be suspended immediately and evaluated.

7.Other serious adverse reactions: including increased serum creatinine, decreased lymphocytes, hypomagnesemia, hypokalemia, decreased platelet count, and hyponatremia. These reactions may require suspension, reduction, or permanent discontinuation of the drug.